Literature DB >> 30328514

How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

Lane B Benes1, Daniel J Brandt2, Eric J Brandt3, Michael H Davidson4.   

Abstract

PURPOSE OF THE REVIEW: To summarize advances in genomic medicine and anticipated future directions to improve cardiovascular risk reduction. RECENT
FINDINGS: Mendelian randomization and genome-wide association studies have given significant insights into the role of genetics in dyslipidemia and cardiovascular disease (CVD), with over 160 gene loci found to be associated with coronary artery disease to date. This has enabled the creation of genetic risk scores that have demonstrated improved risk prediction when added to clinical markers of CVD risk. Incorporation of genomic data into clinical patient care is on the horizon. Genomic medicine is expected to offer improved risk assessment, determination of targeted treatment strategies, and improved detection of lipid disorders causal to CVD development.

Entities:  

Keywords:  Cardiovascular prevention; Genetic risk score for coronary artery disease; Genome-wide association studies; Genomics; Polygenic lipid disorder

Mesh:

Year:  2018        PMID: 30328514     DOI: 10.1007/s11886-018-1079-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  58 in total

1.  Exome sequencing in suspected monogenic dyslipidemias.

Authors:  Nathan O Stitziel; Gina M Peloso; Marianne Abifadel; Angelo B Cefalu; Sigrid Fouchier; M Mahdi Motazacker; Hayato Tada; Daniel B Larach; Zuhier Awan; Jorge F Haller; Clive R Pullinger; Mathilde Varret; Jean-Pierre Rabès; Davide Noto; Patrizia Tarugi; Masa-Aki Kawashiri; Atsushi Nohara; Masakazu Yamagishi; Marjorie Risman; Rahul Deo; Isabelle Ruel; Jay Shendure; Deborah A Nickerson; James G Wilson; Stephen S Rich; Namrata Gupta; Deborah N Farlow; Benjamin M Neale; Mark J Daly; John P Kane; Mason W Freeman; Jacques Genest; Daniel J Rader; Hiroshi Mabuchi; John J P Kastelein; G Kees Hovingh; Maurizio R Averna; Stacey Gabriel; Catherine Boileau; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2015-01-27

Review 2.  Mendelian Randomization.

Authors:  Connor A Emdin; Amit V Khera; Sekar Kathiresan
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

Review 3.  The complex molecular genetics of familial hypercholesterolaemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2019-01       Impact factor: 32.419

Review 4.  Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants.

Authors:  Hayato Tada; Masa-Aki Kawashiri; Masakazu Yamagishi
Journal:  J Hum Genet       Date:  2017-01-05       Impact factor: 3.172

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 6.  Genetics 100 for cardiologists: basics of genome-wide association studies.

Authors:  Joseph B Dubé; Robert A Hegele
Journal:  Can J Cardiol       Date:  2012-11-28       Impact factor: 5.223

7.  Hypertriglyceridemia: phenomics and genomics.

Authors:  Robert A Hegele; Rebecca L Pollex
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

8.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.

Authors:  Amit V Khera; Hong-Hee Won; Gina M Peloso; Kim S Lawson; Traci M Bartz; Xuan Deng; Elisabeth M van Leeuwen; Pradeep Natarajan; Connor A Emdin; Alexander G Bick; Alanna C Morrison; Jennifer A Brody; Namrata Gupta; Akihiro Nomura; Thorsten Kessler; Stefano Duga; Joshua C Bis; Cornelia M van Duijn; L Adrienne Cupples; Bruce Psaty; Daniel J Rader; John Danesh; Heribert Schunkert; Ruth McPherson; Martin Farrall; Hugh Watkins; Eric Lander; James G Wilson; Adolfo Correa; Eric Boerwinkle; Piera Angelica Merlini; Diego Ardissino; Danish Saleheen; Stacey Gabriel; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2016-04-03       Impact factor: 24.094

9.  Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.

Authors:  D Gaudet; J Méthot; S Déry; D Brisson; C Essiembre; G Tremblay; K Tremblay; J de Wal; J Twisk; N van den Bulk; V Sier-Ferreira; S van Deventer
Journal:  Gene Ther       Date:  2012-06-21       Impact factor: 5.250

10.  Genomic prediction of coronary heart disease.

Authors:  Gad Abraham; Aki S Havulinna; Oneil G Bhalala; Sean G Byars; Alysha M De Livera; Laxman Yetukuri; Emmi Tikkanen; Markus Perola; Heribert Schunkert; Eric J Sijbrands; Aarno Palotie; Nilesh J Samani; Veikko Salomaa; Samuli Ripatti; Michael Inouye
Journal:  Eur Heart J       Date:  2016-09-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.